Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Severe COVID-19 is characterized by excessive proinflammatory cytokine production, leading to cytokine release syndrome (CRS) or cytokine storm.
• This hyperinflammatory response is a major factor in COVID-19 pathology and mortality.
• Interleukin-1 (IL-1) plays a critical role in driving this innate immune overreaction.

Purpose of the Study:

• To review the potential of IL-1 blockade agents as a therapeutic strategy for mitigating CRS in COVID-19.
• To assess the safety and efficacy of IL-1 inhibitors based on available case reports and clinical studies.

Main Methods:

• Literature review of case reports and clinical studies.
• Analysis of data on IL-1 inhibitors in the context of COVID-19-associated hyperinflammation.

Main Results:

• IL-1 blockade agents represent a safe approach to controlling overwhelming innate immune responses.
• Preliminary data suggest potential benefits of IL-1 inhibitors in managing hyperinflammatory COVID-19.
• Several IL-1 inhibitors are in observational trials or preliminary reporting stages.

Conclusions:

• IL-1 inhibitors are a promising treatment option for COVID-19 patients experiencing cytokine release syndrome.
• Targeting IL-1 offers a potentially low-toxicity method to manage severe, hyperinflammatory COVID-19.
• Further clinical investigation is warranted to establish the role of IL-1 blockade in COVID-19 treatment.